SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (407)1/4/2000 11:17:00 PM
From: WTDEC  Respond to of 1834
 
The market could have used some CRH1 antagonistic drugs today <G>



To: scaram(o)uche who wrote (407)1/5/2000 12:21:00 AM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 1834
 
If they can repeat results of the initial 20 pts PIIa trials with additional 80 pts (single daily dose, 80 or 160 mg, 28 days), than follow on PIIb and PIII trials are on fast track at J&J.

Also, we should not forget that NBIX have proprietary CRF-R1/R2 combination nex. gen. antagonist compounds which should have broader applications than selective CRF-R1 antagonist.

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News